Regeneron Pharmaceuticals, Inc.

Other

Aventis Pharma S.a.

Jesse M Cedarbaum

Jocelyn Holash

George D Yancopoulos

Neil E Stahl

Eric Steven Furfine

Marie-Christine Bissery

Candelaria Gomez-Manzano

W K Alfred Yung

Patricia Vrignaud

John Rudge

Marielle Chiron-Blondel

Juan Fueyo

This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations.

Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof

A method of reducing or preventing hypertension associated with administration of a vascular endothelial growth factor (VEGF) antagonist in a human subjects suffering from a disease or condition treatable with a VEGF antagonist in which is it desirable to reduce or prevent hypertension. The method is particularly useful for treatment of patients unresponsive to treatment with a VEGF inhibitor administered intravenously.

Methods of treating diseases with a VEGF antagonist

A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and (b) administering to the patient a plurality of subsequent doses of the VEGF antagonist in an amount that is approximately the same or less of the initial dose, wherein the subsequent doses are separated in time from each other by at least one day. The methods of the invention are useful for treating a human cancer selected from the group consisting of renal cell carcinoma, pancreatic carcinoma, breast cancer, prostate cancer, colorectal cancer, malignant mesothelioma, multiple myeloma, ovarian cancer, and melanoma. The invention is further useful for treating a condition which benefits from the reduction of VEGFA and placental growth factor (PLGF).

Method of administering and using VEGF inhibitors for the treatment of non small cell lung cancer

Method of administering and using VEGF inhibitors for the treatment of prostate cancer

Method of administering and using VEGF inhibitors for the treatment of breast cancer

Method of administering and using VEGF inhibitors for the treatment of colorectal cancer

Method of administering and using VEGF inhibitors for the treatment of pancreatic carcinoma

Method of administering and using VEGF inhibitors for the treatment of renal cell cancer

Disclosed are compositions and methods for treating a disease or condition related to angiogenesis with a vascular endothelial growth factor (VEGF) inhibitor and one or more anti-hypertensive agent(s). The method of the invention is useful for preventing the development of hypertension and/or reducing hypertension in a subject treated with a VEGF inhibitor.

Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

Method of administering and using VEGF inhibitors for the treatment of human cancer

Methods for treating a human patient suffering from a brain tumor, including glioblastoma, by administering an effective amount of a vascular endothelial growth factor (VEGF) inhibitor to the human patient. The VEGF inhibitor is a VEGF antagonist protein comprising a dimeric protein having two fusion polypeptides having the sequence of SEQ ID NO:2.

Use of VEGF antagonists for the treatment of malignant gliomas

Methods of treating anemic disorders in human subjects comprising administering a VEGF antagonist comprising a fusion polypeptide having an immunoglobulin-like (Ig) domain 2 of the VEGF receptor Flt1 and Ig domain 3 of the VEGF receptor Flk1 or Flt4, and a multimerizing component. Further included are methods of preventing anemia, increasing hematocrit levels, and increasing or stimulating erythropoietin, particularly in subjects being treated for cancer with chemotherapeutic agents and/or radiation.

Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF)

The present invention relates to methods for enhancing gastrointestinal motility. In particular, the invention relates to the use of neurotrophin-3 and its analogues for enhancing gastrointestinal motility. Methods of using neurotrophin-3 and its analogues for treating gastrointestinal hypomotility disorders are also provided.

Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders

Growing community of inventors

Larchmont, NY, United States of America

Jesse M Cedarbaum